In addition, the downregulation of paxillin can inhibit the ERK signaling pathway to inhibit EMT in colorectal cancer cells by reducing the phosphorylation expression of ERK1/2 while keeping the total ERK1/2 level unchanged [70]. This evidence concerns the gene MAPK3 and colorectal cancer.